Monday 01 December 2025
Internal Reference Number: FOI_8935
Date Request Received: 01/10/2025 00:00:00
Date Request Replied To: 15/10/2025 00:00:00
This response was sent via: By Email
Request Summary: Dermatology and Respiratory medicine
Request Category: Researcher
| Question Number 1: I am analysing the usage of new biologic and targeted medications within dermatology and respiratory medicine. Could you please answer the following questions: How many patients were treated in September 2025 (or latest available month) by the Dermatology department with the following drugs: · Abrocitinib (Cibinqo) · Baricitinib (Olumiant) · Dupilumab (Dupixent) · Lebrikizumab (Ebglyss) · Omalizumab (Xolair) · Tralokinumab (Adtralza) · Upadacitinib (Rinvoq) · Nemolizumab (Nemluvio) | |
| Answer To Question 1: Please see our response in the attached file. To accompany this answer to question 1 please also see the documents listed below:  13276 - FOI_8935 - Dermatology and Respiratory medicine - FOR ISSUE.xlsx | |
| Question Number 2: How many patients were treated in September 2025 (or latest available month) by the Respiratory Medicine departments with the following drugs: · Benralizumab (Fasenra) · Dupilumab (Dupixent) · Mepolizumab (Nucala) · Omalizumab (Xolair) · Reslizumab (Cinqaero) · Tezepelumab (Tezspire) | |
| Answer To Question 2: Please see attached | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
